Friday, 29 March 2024


Singapore strengthens access to liver health education

19 April 2022 | News

Gilead Sciences supports National Foundation of Digestive Diseases with grant funding to improve liver health education in Singapore as part of its Asia Pacific ALL4LIVER Grant

Image credit: shutterstock

Image credit: shutterstock

Gilead Sciences and the National Foundation of Digestive Diseases (NFDD) have announced a new collaborative effort to enhance liver health education in Singapore.

As part of the Gilead Asia Pacific ALL4LIVER Grant program, more than $1 million grant funding has been earmarked to support initiatives to enhance education about viral hepatitis led by community-based organisations across Asia Pacific, with a focus on chronic hepatitis B (HBV).

NFDD is among the first batch of recipients of the ALL4LIVER Grant, and the only organisation from Singapore. Currently, HBV causes 60-70% of the total number of liver cancer cases in the country.

NFDD is a long established Singaporean non-profit organisation which serves to improve among the general public, knowledge and awareness of diseases affecting the digestive and liver system. 

The Gilead Asia Pacific ALL4LIVER Grant was inspired by a large-scale Asian liver health study which identified critical knowledge gaps and attitudes of the general population towards liver health. An online survey conducted with 7,500 respondents across 11 countries/territories: Singapore, Hong Kong, India, Indonesia, Malaysia, Pakistan, Philippines, South Korea, Taiwan, Thailand, and Vietnam.

The ALL4LIVER Grant targets 11 countries/ territories across the Asia Pacific region – same as those from the Liver Index Study. Submissions focused on strengthening peer support, improving awareness, literacy, and innovation in hepatitis B.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account